Stereoselective 4'-hydroxylation of phenytoin: Relationship to (S)-mephenytoin polymorphism in Japanese

British Journal of Clinical Pharmacology

Volumn 43, Issue 4, 1997, Pages 441-445

  Ieiri, I ^a   Mamiya, K ^a   Urae, A ^b   Wada, Y ^a   Kimura, M ^a   Irie, S ^b   Amamoto, T ^b   Kubota, T ^c   Yoshioka, S ^c   Nakamura, K ^d   Nakano, S ^d   Tashiro, N ^e   Higuchi, S ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Kyushu Pharmacology Research Clinic   (Japan)

^c SRL INC   (Japan)

^d OITA UNIVERSITY   (Japan)

^e KYUSHU UNIVERSITY   (Japan)

Author keywords

CYP2C19; CYP2C9; Omeprazole; Phenytoin; Stereoselective hydroxylation

Indexed keywords

DRUG METABOLITE; MEPHENYTOIN; OMEPRAZOLE; PHENYTOIN;

ARTICLE; DRUG METABOLISM; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; HYDROXYLATION; JAPAN; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; STEREOSPECIFICITY; VOLUNTEER;

EID: 8244261385     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.00572.x     Document Type: Article

References (21)

1. Andersson T, Regardh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992; 2: 25-31.
2. Bertilsson L, Kalow W. Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in White and Korean populations but not in Chinese population? Clin Pharmacol Ther 1993; 53: 608-610.
3. Ward SA, Helsby NA, Skjelbo E, Brosen K, Gram LF, Breckenridge AM. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism - a panel study. Br J Clin Pharmacol 1991; 31: 689-692.
4. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994; 4: 285-299.
5. Fritz S, Lindner W, Roots I, Frey BM, Kupfer A. Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans. J Pharmacol Exp Ther 1987; 241: 615-621.
6. Ieiri I, Goto W, Hirata K, et al. Effect of 5-(p-hydroxyphenyl)-5-phenylhydantoin (p-HPPH) enantiomers, major metabolites of phenytoin, on the occurrence of chronic-gingival hyperplasia: in vivo and in vitro study. Eur J Clin Pharmacol 1995; 49: 51-56.
7. Ieiri I, Kubota T, Urae A, et al. Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese. Clin Pharmacol Ther 1996; 59: 647-653.
8. Wang SL, Huang JD, Lai MD, Tsai JJ. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995; 5: 37-42.
9. Eto S, Noda H, Noda A. Simultaneous determination of antiepileptic drugs and their metabolites, including chiral compounds, via β-cyclodextrin inclusion complexes by a column-switching Chromatographic technique. J Chromatogr B 1994; 658: 385-390.
10. Kutt H, Wolk M, Scherman R, McDowell F. Insufficient parahydroxylation as a cause of diphenylhydantoin toxicity. Neurology 1964; 14: 542-548.
11. Andreasen PB, Froland A, Skovsted L, Anderson SA, Hauge M. Diphenylhydantoin half-life in man and its inhibition by phenylbutazone; the role of genetic factors. Acta Med Scand 1973; 193: 561-564.
12. Vermeij P, Ferrari MD, Buruma OJS, Veenema H, de Wolff FA. Inheritance of poor phenytoin parahydroxylation capacity in a dutch family. Clin Pharmacol Ther 1988; 44: 588-593.
13. de Wolff FA, Vermeij P, Ferrari MD, Buruma OJS, Breimer DD. Impairment of phenytoin parahydroxylation as a cause of severe intoxication. Ther Drug Monit 1983; 5: 213-215.
14. Inaba T, Jurima M, Mahon WH, Kalow W. In vitro inhibition studies of two isozymes of human liver cytochrome P-450: Mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab Dispos 1985; 13: 443-148.
15. Jackson PR, Tucker GT, Lennard MS, Woods HF. Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. Br J Clin Pharmacol 1986; 22: 541-550.
16. Chang M, Dahl ML, Tybring G, Gotharson E, Bertilsson L. Use of omeprazole as a probe for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995; 5: 358-363.
17. Chang M, Tybring G, Dahl ML, et al. Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995; 39: 511-518.
18. Balian JD, Sukhova N, Harris JW, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study. Clin Pharmacol Ther 1995; 57: 662-669.
19. Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, Birkett DJ. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun 1991; 175: 1112-1118.
20. Veronese ME, Doecke CJ, Mackenzie PI, et al. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem J 1993; 289: 533-538.
21. Yasumori T, Kawano S, Nagata K, Shimada M, Yamazoe Y, Kato R. Nucleotide sequence of a human liver cytochrome P450 related to the rat male specific forms. J Biochem 1987; 102: 1075-1082.